80 reports

Market Spotlight: Cervical Cancer CONTENTS ## OVERVIEW ## KEY TAKEAWAYS ## DISEASE BACKGROUND ## TREATMENT ## Surgery ## Radiotherapy ## Chemotherapy ## Targeted therapy ## EPIDEMIOLOGY ## MARKETED DRUGS ## Approvals by country ## PIPELINE DRUGS ## KEY UPCOMING EVENTS ## LICENSING AND ASSET ACQUIS

  • Cancer
  • Cervical Cancer
  • United States
  • World
  • Market Description

Gastric cancer

4546 5000 3864

Gastric Cancer, ##(##), ##-## < PMID> ##< / PMID>.

  • Cancer
  • East Asia
  • Japan
  • United States
  • Eli Lilly & Co.

Head and neck cancer

4546 5000 3864

Nature Reviews Cancer, ##(##), ##-## < DOI> ##. ##/ nrc##< / DOI>.

  • Cancer
  • United States
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.

& nbsp; Most payers however will wait for the ovarian cancer market to mature before they deploy any contracts for preferred products.

  • Cancer
  • Ovarian Cancer
  • Therapy
  • European Union
  • United States

Colorectal cancer

4546 5000 3864

Cancer Prevention Research, ##(##), ##-## < DOI> ##. ##/ ##-##.

  • Cancer
  • European Union
  • Japan
  • North America
  • United States

Pancreatic cancer

4546 5000 3864

BIBLIOGRAPHY Pancreatic cancer Disease Coverage | Forecast: Pancreatic Cancer DMKC## US ## ## ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ##

  • Cancer
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • NewLink Genetics Corporation
  • Taiho Pharmaceutical Co., Ltd.

Source: Datamonitor Healthcare ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## < ##. ## < ##. ## < ##. ## < ##. ## < ##. ## < ##. ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Cancer
  • Japan
  • United States
  • ArQule, Inc.
  • Eli Lilly & Co.

Breast Cancer Research and Treatment, ##(##), ##-## < DOI> ##. ##/ eat. ##.

  • Cancer
  • European Union
  • Japan
  • United States
  • TESARO, Inc.

NERATINIB FORECAST, 2013-## FIGURE ##: NERATINIB SALES FORECAST FOR HER##-POSITIVE BREAST CANCER IN THE US, JAPAN, AND FIVE MAJOR EU MARKETS, BY COUNTRY ($M), 2013-## Breast cancer: HER##-positive Disease Coverage | Forecast: HER##- Positive Breast Cancer DMKC## FIGURE ##:

  • Cancer
  • European Union
  • United States
  • GlaxoSmithKline plc
  • Roche Group

Renal cell cancer

4546 5000 3864

Renal cell cancer Disease Coverage | Forecast: Renal Cell Cancer Table ##: RCC drug sales in the US, Japan, and five major EU markets ($m), 2013-## Renal cell cancer Disease Coverage | Forecast: Renal Cell Cancer PD-##/ PD-L## INHIBITORS WILL GE

  • Cancer
  • European Union
  • Japan
  • North America
  • United States

Gastric Cancer Forecast and Market Analysis to 2024 FORECAST: GASTRIC CANCER (Published on ## December 2017) EXECUTIVE SUMMARY RECENT FORECAST UPDATES MARKET DYNAMICS FORECAST AND FUTURE TRENDS MARKET DEFINITION AND METHODOLOGY PRIMARY RESEARCH METHODOLOGY BIBLIOGRAPHY PRODUCT PROF

  • Cancer
  • Gastric Cancer
  • European Union
  • Japan
  • United States

Colorectal Cancer Forecast and Market Analysis to 2036 FORECAST: COLORECTAL CANCER IN THE US, JAPAN, AND ##EU (Published on ## December 2017) EXECUTIVE SUMMARY RECENT FORECAST UPDATES MARKET DYNAMICS FORECAST AND FUTURE TRENDS MARKET DEFINITION AND METHODOLOGY PRIMARY RESEARCH METHO

  • Cancer
  • European Union
  • Japan
  • United States
  • Demand

Renal cell cancer (RCC) disease forecast and market analysis to 2035 CONTENTS (Full Disease Coverage) & nbsp; ## FORECAST: RENAL CELL CANCER (Published on ## March 2017) ## EXECUTIVE SUMMARY ## MARKET OVERVIEW AND TRENDS ## METHODOLOGY AND MARKET DEFINITION ## AFINITOR (EVEROLIM

  • Cancer
  • Renal Cancer
  • European Union
  • Japan
  • United States

Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024 FORECAST: PROSTATE CANCER (Published on ## January 2018) EXECUTIVE SUMMARY MARKET DYNAMICS FORECAST AND FUTURE TRENDS MARKET DEFINITION AND METHODOLOGY PRIMARY RESEARCH METHODOLOGY BIBLIOGRAPHY PRODUCT PROFILE (L

  • Cancer
  • European Union
  • Japan
  • United States
  • Demand

Prostate cancer

4546 5000 3864

The Cancer Journal, ##(##), ##-##, < DOI> ##. ##/ PPO. ##b##e##a< / DOI>.

  • Cancer
  • Europe
  • European Union
  • North America
  • United States

Cervical Cancer Disease Coverage Forecast and Market Analysis to 2023 CONTENTS ## EPIDEMIOLOGY: CERVICAL CANCER ## Executive Summary ## Disease Background ## Sources and Methodology ## Forecast ## Epidemiologist Insight ## Strengths and Limitations ## APPENDIX ## Appendix: Epidemiol

  • Cancer
  • Cervical Cancer
  • European Union
  • Japan
  • United States

The future of NSCLC treatment will reflect the era of personalized therapies as mutation status becomes one of the main determinants of treatment choice.

  • Cancer
  • European Union
  • Japan
  • United States
  • Demand

AVAILABLE FROM: HTTP:/ / WWW. ICHOM. ORG/ MEDICALCONDITIONS/ ADVANCED-PROSTATE-CANCER/ [ACCESSED ## JUNE 2016].

  • Cancer
  • Hormone
  • Hospital
  • Therapy
  • United States

Drug Overview: Rubraca

9091 10000 7727

Drug Overview: Rubraca TABLE OF CONTENTS ## Product Profiles ## Rubraca : Prostate cancer ## Rubraca : Ovarian cancer LIST OF FIGURES ## Figure ##: Rubraca for prostate cancer – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Rubraca fo

  • Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • European Union
  • United States

Drug Analysis: Rubraca

9091 10000 7727

Drug Analysis: Rubraca Product Profiles Rubraca : Prostate cancer Rubraca : Ovarian cancer LIST OF FIGURES Figure ##: Rubraca for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Rubraca for prostate cancer Fig

  • Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • European Union
  • United States

Drug Analysis: Yonsa

9091 10000 7727

Drug Analysis: Yonsa Product Profiles Yonsa : Prostate cancer LIST OF FIGURES Figure ##: Yonsa for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Yonsa for prostate cancer Figure ##: Datamonitor Healthcare’s drug asses

  • Cancer
  • Hormone
  • Prostate Cancer
  • Therapy
  • United States

Drug analysis: OncoVAX

9091 10000 7727

Drug analysis: OncoVAX Product Profiles OncoVAX : Colorectal cancer (CRC) LIST OF FIGURES Figure ##: OncoVAX for colon cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of OncoVAX for colon cancer Figure ##: Datamonitor Healthcare’s

  • Cancer
  • Pathology
  • United States

Drug Analysis: DCVAC/ PCa Product Profiles DCVAC/ PCa : Prostate cancer LIST OF FIGURES Figure ##: DCVAC/ PCa for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of DCVAC/ PCa for prostate cancer Figure ##:

  • Cancer
  • Cell Therapy
  • European Union
  • Japan
  • United States

Drug Overview: DCVAC/ PCa TABLE OF CONTENTS ## Product Profiles ## DCVAC/ PCa : Prostate cancer LIST OF FIGURES ## Figure ##: DCVAC/ PCa for prostate cancer – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of DCVAC/ PCa for prosta

  • Cancer
  • Cell Therapy
  • European Union
  • Japan
  • United States

Drug Analysis: Jevtana

9091 10000 7727

Drug Analysis: Jevtana Product Profiles Jevtana : Prostate cancer LIST OF FIGURES Figure ##: Jevtana for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Jevtana for prostate cancer Figure ##: Datamonitor Healthcare’s dr

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States

Drug Analysis: Zytiga

9091 10000 7727

Drug Analysis: Zytiga Product Profiles Zytiga : Prostate cancer LIST OF FIGURES Figure ##: Zytiga for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Zytiga for prostate cancer Figure ##: Datamonitor Healthcare’s drug a

  • Cancer
  • European Union
  • Japan
  • United States
  • Supply

Drug Overview: Zytiga

9091 10000 7727

Drug Overview: Zytiga TABLE OF CONTENTS ## Product Profiles ## Zytiga : Prostate cancer LIST OF FIGURES ## Figure ##: Zytiga for prostate cancer – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Zytiga for prostate cancer ## Figure ##:

  • Cancer
  • European Union
  • Japan
  • United States
  • Supply

Drug Analysis: darolutamide Product Profiles darolutamide : Prostate cancer LIST OF FIGURES Figure ##: Darolutamide for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of darolutamide for prostate cancer Figure ##: Datamon

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States

Drug Analysis: Xtandi

9091 10000 7727

Drug Analysis: Xtandi Product Profiles Xtandi : Prostate cancer LIST OF FIGURES Figure ##: Xtandi for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Xtandi for prostate cancer Figure ##: Datamonitor Healthcare’s drug a

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States

Drug Overview: Xtandi

9091 10000 7727

Drug Overview: Xtandi TABLE OF CONTENTS ## Product Profiles ## Xtandi : Prostate cancer LIST OF FIGURES ## Figure ##: Xtandi for prostate cancer – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Xtandi for prostate cancer ## Figure ##:

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States